Immix Biopharma, Inc. · NASDAQ:IMMX
Immix Biopharma — Investor Presentation (December 2022)
17 slides from Immix Biopharma's investor presentation, Dec 16, 2022
Slide 1: Next Generation Cell Therapies
© , NEXCELLA NEXT GENERATION CELL THERAPIES Next Generation Cell Therapies Targeting Oncology & Other Diseases December 2022
Slide 2: Forward Looking Statements
Forward Looking Statements NEXCELLA This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Nexcella, Inc. (the “Company’) strateg
Slide 3: Mission
Mission © NEXCELLA hed ro Harness the power of cell-th to rapidly engineer safe, eff accessible treatments to improve patient outcomes in oncology and other indications — beginning with what we believe is the first outpatient CAR-T.
Slide 4: Large Markets
Large Markets NEXCELS Hematologic cancers market opportunity is $60bn today growing to $120bn in 2028. * Multiple Myeloma (“MM”) is 3rd 6,404 patients annually, \ “Patients With Multiple Myeloma May Face CAR T-Cell Shortages” he ASCO Post September 25, 2022 * ALAmyloidosis is Uh Bristol Myers FAbed
Slide 5: N-GENIUS Platform: NXC-201 Preclinical Highlights
N-GENIUS Platform: NXC-201 Preclinical Highlights ® \ NEXCELLA N-GENIUS PLATFORM High Transduction Efficiency 7 Purpose-Built Cell Therapy Evidence Capture Pe Engine + Relational Database 6 Proprietary EXPAND technology Low Tonic Signaling 87.7432 . oe Anti-Exhaustion Capability , Atomized, Novel Bi
Slide 6: NXC-201 AL Amyloidosis Market
NXC- ne Market ®. NEXCELLA 1d Light Chain (AL chain (AL) Amyloidosis A ARCELLX ih Bristol Myers Fichwonafohwen (olinren afohrren Coane - Soulbb Q 3 <Roche (NASDAQ: ACLX) TAbecma SS CARWYKT ise CART-ddBCMA moore . aN Patient #s n=31 n=100 n=97 Patient #s n=388 n=43 Extramedullary disease = si ss Fore
Slide 7: NXC-201 Clinical Data
NXC-201 Cl G@SNEXCELLA @SNEXCELLA All dose le Patient #s Extramedullary disease (EMD) High risk cytogenetics ORR 85 75 | Neurotoxcity | 2 Grade __ CRS, grade >= 3 Se Clinical Data Tocilizumab co-administration to combat CRS Source ® | NEXCELLA G@SNEXCELLA NXC-201 All Dose Levels Patient #s =4 | Orga
Slide 8: NXC-201 Clinical Highlights
NXC-201 Clinical Highlights (2 ) ® . NEXCELLA Aultiple Myeloma and Light Ct Co) Li chain (AL) Amyloidosis Duration of Response Not Yet Reached at a median follow-up of 5.2 months ) 71% CR SCR (SCR 10°) rate in Heavily Pretreated Multiple Myeloma Patients (85% Overall Response) No Neurotoxicity obser
Slide 9: Clinical Development Plan
Clinical Development Plan Multiple Myeloma | NXC-201 Relapsed/refractory Multiple Myeloma 97 patients At RP2D Establish MTD / RP2D Clinical Effectiveness Submit to FDA ® | NEXCELLA Ongoing AL Amyloidosis Phase 2 NXC-201 NXC-201 Relapsed/refractory Light Chain (AL) Amyloidosis >30 Patients Submit to
Slide 10: NXC-201 Best in Class Potential
NXC-201 Best in Cle Potentia Multiple Myeloma NXC-201 (n=20) AL Amyloidosis NXC-201 (n=4) n Multiple Myelc High Complete Response Rates 71% CR/SCR 85% ORR 100% CR 100% Organ Response Rate No Neurotoxicity Observed To-Date No ICANS No Neurotoxicity No ICANS No Neurotoxicity NEXCELLA Potential Outpati
Slide 11: Pipeline
Pipeline NEXCELLA Status Indication Preclinical Phase 1 Phase 2 Phase 3 Approval Global Rights i” ; 1 | Multiple Myeloma 20 Patients treated €SNEXCELLA | eee cree ee ean eee eee eee es eee eee cee eee al fost 4 patients treated AL Amyloidosis ww CR iboK creanresnorserate SS PNEXCELLA ALL Preclinical
Slide 12: Overview
Overview NEXCELLA Positive Clinical Results In >40 Patients Proprietary N-GENIUS Platform, already produced NXC-201, poised to potentially bring numerous CAR-Ts to market in succession Massive Market Opportunity Multiple Potential Catalysts 71% CR/SCR Rate in Multiple Myeloma: World class clinical d
Slide 13: Next Generation Cell Therapies
© , NEXCELLA NEXT GENERATION CELL THERAPIES Next Generation Cell Therapies Targeting Oncology & Other Diseases
Slide 14: Adverse Event Profile - Market
Adverse Event Profile - Market NEXCELLA AQ ARCELLX =A ARCELLX 100 x10° cells 300x10° cells n=25 n=6 Grade 3-4 Grade 3-4 Adverse Events cytokine Release Syndrome (CRS) —SCiH)SSSSCSC~CS~«Y | Day of median onset (min-max) 0 (0%) 0 (0%) | l Days of median duration (min-max) 0 (0%) 0 (0%) | el tae 1 vam
Slide 15: Adverse Event Profile
Adverse Event Profile NEXCELLA CSNEXCELLA (SNEXCELLA (SNEXCELLA 150x10° cells 450x10° cells 800x10° cells n=6 n=7 n=7 Grade 3-4 Grade 3-4 Grade 3-4 Adverse Events Tcytokine Release Syndrome(ck) | SM)SS:*—*=<“*‘Sé~CS OHSCOC*“‘“‘C#C‘CUOMY!SC*# | | Day of median onset (min-max) 0 (0%) 0 (0%) 0 (0%) | |
Slide 16: Proportion of NXC-201 Patients with sCR/CR Increased Over Time
Proportion of NXC-201 Patients with sCR/CR Increased Over Time in Relapsed/Refractory Multiple Myeloma gSD mPR mVGPR sCR/CR 50% 60% 83% Best response in patients with Best response in patients with Best response in patients with at least 1 month follow up at least 6 months follow up at least 9 month
Slide 17: Next Generation Cell Therapies
© ,NEXCELLA NEXT GENERATION CELL THERAPIES Next Generation Cell Therapies Targeting Oncology & Other Diseases
Immix Biopharma — Investor Presentation (December 2022) on 6ix